Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and Primary School-Aged Children

Figure 3

Effect of praziquantel treatment on levels of urinary markers of schistosome-related morbidity 12 months after treatment. (a) Microhaematuria, (b) proteinuria, and (c) albuminuria. Error bars indicate 95% CI and the values for pairwise comparisons are from the generalized linear mixed models investigating the probability of a child presenting with morbidity markers before and after treatment, adjusted for sex and age group. Significant values are marked with .

(a)

(b)

(c)